Sulfasalazine
 Sulfasalazine Delayed Release Tablets

drug-information.ru

|Sulfasalazine Sulfasalazine Delayed Release Tablets

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Sulfasalazine


Generic Name: Sulfasalazine
Dosage Form: Tablets usp

Sulfasalazine Description

Sulfasalazine Tablets USP, 500 mg for Oral Administration

Therapeutic classification: Anti-inflammatory agent.

Chemical designation: 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid.

Chemical Structure:

C18H14N4O5S

The molecular weight of Sulfasalazine is 398.39.

Inactive Ingredients: magnesium stearate, pregelatinized starch, sodium starch glycolate and stearic acid.

Sulfasalazine - Clinical Pharmacology

Pharmacodynamics

The mode of action of Sulfasalazine (SSZ) or its metabolites, 5-amino­salicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of SSZ, SP, and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety.

Pharmacokinetics

In vivo studies have indicated that the absolute bioavailability of orally administered SSZ is less than 15% for parent drug. In the intestine, SSZ is metabolized by intestinal bacteria to SP and 5-ASA. Of the two species, SP is relatively well absorbed from the intestine and highly metabolized, while 5-ASA is much less well absorbed.

Absorption

Following oral administration of 1 g of SSZ to 9 healthy males, less than 15% of a dose of SSZ is absorbed as parent drug. Detectable serum concentrations of SSZ have been found in healthy subjects within 90 minutes after the ingestion. Maximum concentrations of SSZ occur between 3 and 12 hours post-ingestion, with the mean peak concentration (6 mcg/mL) occurring at 6 hours.

In comparison, peak plasma levels of both SP and 5-ASA occur approximately 10 hours after dosing. This longer time to peak is indicative of gastrointestinal transit to the lower intestine where bacteria-mediated metabolism occurs. SP apparently is well absorbed from the colon with an estimated bioavailability of 60%. In this same study, 5-ASA is much less well absorbed from the gastrointestinal tract with an estimated bioavailability of from 10% to 30%.

Distribution

Following intravenous injection, the calculated volume of distribution (Vdss) for SSZ was 7.5 ± 1.6 L. SSZ is highly bound to albumin (>99.3%), while SP is only about 70% bound to albumin. Acetylsulfapyridine (AcSP), the principal metabolite of SP, is approximately 90% bound to plasma proteins.

Metabolism

As mentioned above, SSZ is metabolized by intestinal bacteria to SP and 5-ASA. Approximately 15% of a dose of SSZ is absorbed as parent and is metabolized to some extent in the liver to the same two species. The observed plasma half-life for intravenous Sulfasalazine is 7.6 ± 3.4 hours. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. In fast acetylators, the mean plasma half-life of SP is 10.4 hours, while in slow acetylators, it is 14.8 hours. SP can also be metabolized to 5-hydroxy-sulfapyridine (SPOH) and N-acetyl-5-hydroxy-sulfapyridine. 5-ASA is primarily metabolized in both the liver and intestine to N-acetyl-5-aminosalicylic acid via a non-acetylation phenotype dependent route. Due to low plasma levels produced by 5-ASA after oral administration, reliable estimates of plasma half-life are not possible.

Excretion

Absorbed SP and 5-ASA and their metabolites are primarily eliminated in the urine either as free metabolites or as glucoronide conjugates. The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. The calculated clearance of SSZ following intravenous administration was 1 L/hr. Renal clearance was estimated to account for 37% of total clearance.

Special Populations

Elderly

Elderly patients with rheumatoid arthritis showed a prolonged plasma half-life for SSZ, SP, and their metabolites. The clinical impact of this is unknown.

Pediatric

Small studies have been reported in the literature in children down to the age of 4 years with ulcerative colitis and inflammatory bowel disease. In these populations, relative to adults, the pharmacokinetics of SSZ and SP correlated poorly with either age or dose.

Acetylator Status

The metabolism of SP to AcSP is mediated by polymorphic enzymes such that two distinct populations of slow and fast metabolizers exist. Approximately 60% of the Caucasian population can be classified as belonging to the slow acetylator phenotype. These subjects will display a prolonged plasma half-life for SP (14.8 hours vs 10.4 hours) and an accumulation of higher plasma levels of SP than fast acetylators. The clinical implication of this is unclear; however, in a small pharmacokinetic trial where acetylator status was determined, subjects who were slow acetylators of SP showed a higher incidence of adverse events.

Gender

Gender appears not to have an effect on either the rate or the pattern of metabolites of SSZ, SP, or 5-ASA.

Indications and Usage for Sulfasalazine

Sulfasalazine tablets are indicated:

a. in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and

b. for the prolongation of the remission period between acute attacks of ulcerative colitis.

Contraindications

Sulfasalazine tablets are contraindicated in:

Patients with intestinal or urinary obstruction,

Patients with porphyria,

Patients hypersensitive to Sulfasalazine, its metabolites, sulfonamides or salicylates.

Warnings

Only after critical appraisal should Sulfasalazine tablets be given to patients with hepatic or renal damage or blood dyscrasias. Deaths associated with the administration of Sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis. The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders. Complete blood counts, as well as urinalysis with careful microscopic examination, should be done frequently in patients receiving Sulfasalazine (see PRECAUTIONS, Laboratory Tests). Oligospermia and infertility have been observed in men treated with Sulfasalazine; however, withdrawal of the drug appears to reverse these effects.

Precautions

General

Sulfasalazine tablets should be given with caution to patients with severe allergy or bronchial asthma. Adequate fluid intake must be maintained in order to prevent crystalluria and stone formation. Patients with glucose-6 phosphate dehydrogenase deficiency should be observed closely for signs of hemolytic anemia. This reaction is frequently dose related. If toxic or hypersensitivity reactions occur, the drug should be discontinued immediately.

Information for Patients

Patients should be informed of the possibility of adverse effects and of the need for careful medical supervision. The occurrence of sore throat, fever, pallor, purpura, or jaundice may indicate a serious blood disorder. Should any of these occur, the patient should seek medical advice. They should also be made aware that ulcerative colitis rarely remits completely, and that the risk of relapse can be substantially reduced by continued administration of Sulfasalazine at a maintenance dosage. Patients should be instructed to take Sulfasalazine in evenly divided doses, preferably after meals. Additionally, patients should be advised that Sulfasalazine may produce an orange-yellow discoloration of the urine or skin.

Laboratory Tests

Complete blood counts, including differential white cell count and liver function tests, should be performed before starting Sulfasalazine and every second week during the first three months of therapy. During the second three months, the same tests should be done once monthly and thereafter once every three months, and as clinically indicated. Urinalysis and an assessment of renal function should also be done periodically during treatment with Sulfasalazine.

The determination of serum sulfapyridine levels may be useful since concentrations greater than 50 mcg/mL appear to be associated with an increased incidence of adverse reactions.

Drug Interactions

Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with Sulfasalazine.

Drug/Laboratory Test Interactions

The presence of Sulfasalazine or its metabolites in body fluids has not been reported to interfere with laboratory test procedures.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Two-year oral carcinogenicity studies were conducted in male and female F344/N rats and B6C3F1 mice. Sulfasalazine was tested at 84 (496 mg/m²), 168 (991 mg/m²), and 337.5 (1991 mg/m²) mg/kg/day doses in rats. A statistically significant increase in the incidence of urinary bladder transitional cell papillomas was observed in male rats. In female rats, two (4%) of the 337.5 mg/kg rats had transitional cell papilloma of the kidney. The increased incidence of neoplasms in the urinary bladder and kidney of rats was also associated with an increase in the renal calculi formation and hyperplasia of transitional cell epithelium. For the mouse study, Sulfasalazine was tested at 675 (2025 mg/m²), 1350 (4050 mg/m²), and 2700 (8100 mg/m²) mg/kg/day. The incidence of hepatocellular adenoma or carcinoma in male and female mice was significantly greater than the control at all doses tested.

Sulfasalazine did not show mutagenicity in the bacterial reverse mutation assay (Ames test) and in L51784 mouse lymphoma cell assay at the HGPRT gene. However, Sulfasalazine showed equivocal mutagenic response in the micronucleus assay of mouse and rat bone marrow and mouse peripheral RBC and in the sister chromatid exchange, chromosomal aberration, and micronucleus assays in lymphocytes obtained from humans.

Impairment of male fertility was observed in reproductive studies performed in rats at a dose of 800 mg/kg/day (4800 mg/m²). Oligospermia and infertility have been described in men treated with Sulfasalazine. Withdrawal of the drug appears to reverse these effects.

Pregnancy

Teratogenic Effects

Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 6 times the human dose and have revealed no evidence of impaired female fertility or harm to the fetus due to Sulfasalazine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. A national survey evaluated the outcome of pregnancies associated with inflammatory bowel disease (IBD). In a group of 186 women treated with Sulfasalazine alone or Sulfasalazine and concomitant steroid therapy, the incidence of fetal morbidity and mortality was comparable to that for 245 untreated IBD pregnancies, as well as to pregnancies in the general population.¹ A study of 1,455 pregnancies associated with exposure to sulfonamides indicated that this group of drugs, including Sulfasalazine, did not appear to be associated with fetal malformation.² A review of the medical literature covering 1,155 pregnancies in women with ulcerative colitis suggested that the outcome was similar to that expected in the general population.³

No clinical studies have been performed to evaluate the effect of Sulfasalazine on the growth development and functional maturation of children whose mothers received the drug during pregnancy.

Nonteratogenic Effects

Sulfasalazine and sulfapyridine pass the placental barrier. Although sulfapyridine has been shown to have a poor bilirubin-displacing capacity, the potential for kernicterus in newborns should be kept in mind.

A case of agranulocytosis has been reported in an infant whose mother was taking both Sulfasalazine and prednisone throughout pregnancy.

Nursing Mothers

Caution should be exercised when Sulfasalazine is administered to a nursing woman. Sulfonamides are excreted in the milk. In the newborn, they compete with bilirubin for binding sites on the plasma proteins and may thus cause kernicterus. Insignificant amounts of uncleaved Sulfasalazine have been found in milk, whereas the sulfapyridine levels in milk are about 30% to 60% of those in the maternal serum. Sulfapyridine has been shown to have a poor bilirubin-displacing capacity.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of two years have not been established.

Adverse Reactions

The most common adverse reactions associated with Sulfasalazine are anorexia, headache, nausea, vomiting, gastric distress, and apparently reversible oligospermia. These occur in about one-third of the patients. Less frequent adverse reactions are skin rash, pruritis, urticaria, fever, Heinz body anemia, hemolytic anemia, and cyanosis, which may occur at a frequency of one in every thirty patients or less. Experience suggests that with a daily dosage of 4 g or more, or total serum sulfapyridine levels above 50 mcg/mL, the incidence of adverse reactions tends to increase. Although the listing which follows includes a few adverse reactions which have not been reported with this specific drug, the pharmacological similarities among the sulfonamides require that each of these reactions be considered when Sulfasalazine tablets are administered. Less common or rare adverse reactions include:

Blood dyscrasias: aplastic anemia, agranulocytosis, leukopenia, megaloblastic (macrocytic) anemia, purpura, thrombocytopenia, hypoprothrombinemia, methemoglobinemia, congenital neutropenia, and myelodysplastic syndrome.

Hypersensitivity reactions: erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, epidermal necrolysis (Lyell’s syndrome) with corneal damage, anaphylaxis, serum sickness syndrome, pneumonitis with or without eosinophilia, vasculitis, fibrosing alveolitis, pleuritis, pericarditis with or without tamponade, allergic myocarditis, polyarteritis nodosa, lupus erythematosus-like syndrome, hepatitis and hepatic necrosis with or without immune complexes, fulminant hepatitis, sometimes leading to liver transplantation, parapsoriasis varioliformis acuta (Mucha-Haberman syndrome), rhabdomyolysis, photosensitization, arthralgia, periorbital edema, conjunctival and scleral injection, and alopecia.

Gastrointestinal reactions: hepatitis, pancreatitis, bloody diarrhea, impaired folic acid absorption, impaired digoxin absorption, stomatitis, diarrhea, abdominal pains, and neutropenic enterocolitis.

Central nervous system reactions: transverse myelitis, convulsions, meningitis, transient lesions of the posterior spinal column, cauda equina syndrome, Guillian-Barre syndrome, peripheral neuropathy, mental depression, vertigo, hearing loss, insomnia, ataxia, hallucinations, tinnitus, and drowsiness.

Renal reactions: toxic nephrosis with oliguria and anuria, nephritis, nephrotic syndrome, urinary tract infections, hematuria, crystalluria, proteinuria, and hemolytic-uremic syndrome.

Other reactions: urine discoloration and skin discoloration.

The sulfonamides bear certain chemical similarities to some goitrogens, diuretics (acetazolamide and the thiazides), and oral hypoglycemic agents. Goiter production, diuresis and hypoglycemia have occurred rarely in patients receiving sulfonamides. Cross-sensitivity may exist with these agents. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides and long-term administration has produced thyroid malignancies in this species.

Postmarketing Reports

The following events have been identified during post-approval use of products which contain (or are metabolized to) mesalamine in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of seriousness, frequency of reporting, or potential causal connection to mesalamine:

Gastrointestinal: Reports of hepatotoxicity, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin),jaundice,cholestatic jaundice,cirrhosis,and possible hepatocellular damage including liver necrosis and liver failure. Some of these cases were fatal. One case of Kawasaki-like syndrome, which included hepatic function changes, was also reported.

Drug Abuse and Dependence

None reported.

Overdosage

There is evidence that the incidence and severity of toxicity following overdosage are directly related to the total serum sulfapyridine concentration. Symptoms of overdosage may include nausea, vomiting, gastric distress and abdominal pains. In more advanced cases, central nervous system symptoms such as drowsiness, convulsions, etc. may be observed. Serum sulfapyridine concentrations may be used to monitor the progress of recovery from overdosage.

There are no documented reports of deaths due to ingestion of large single doses of Sulfasalazine. A single oral dose of 12 g/kg was not lethal to mice.

Instructions for Overdosage: Gastric lavage or emesis plus catharsis as indicated. Alkalinize urine. If kidney function is normal, force fluids. If anuria is present, restrict fluids and salt, and treat appropriately. Catheterization of the ureters may be indicated for complete renal blockage by crystals. The low molecular weight of Sulfasalazine and its metabolites may facilitate their removal by dialysis.

Sulfasalazine Dosage and Administration

The dosage of Sulfasalazine tablets should be adjusted to each individual’s response and tolerance.

Initial Therapy

Adults: 3 to 4 g daily in evenly divided doses with dosage intervals not exceeding eight hours. In some cases, it is advisable to initiate therapy with a smaller dosage, e.g. 1 to 2 g daily, to reduce possible gastrointestinal intolerance. If daily doses exceeding 4 g are required to achieve desired effects, the increased risk of toxicity should be kept in mind.

Children, six years of age and older: 40 to 60 mg/kg body weight in each 24­hour period, divided into 3 to 6 doses.

Maintenance Therapy:

Adults: 2 g daily.

Children, six years of age and older: 30 mg/kg body weight in each 24-hour period, divided into 4 doses.

The response of acute ulcerative colitis to Sulfasalazine tablets can be evaluated by clinical criteria, including the presence of fever, weight changes, and degree and frequency of diarrhea and bleeding, as well as by sigmoidoscopy and the evaluation of biopsy samples. It is often necessary to continue medication even when clinical symptoms, including diarrhea, have been controlled. When endoscopic examination confirms satisfactory improvement, the dosage of Sulfasalazine should be reduced to a maintenance level. If diarrhea recurs, dosage should be increased to previously effective levels. If symptoms of gastric intolerance (anorexia, nausea, vomiting, etc.) occur after the first few doses of Sulfasalazine, they are probably due to increased serum levels of total sulfapyridine and may be alleviated by halving the daily dose of Sulfasalazine and subsequently increasing it gradually over several days. If gastric intolerance continues, the drug should be stopped for 5 to 7 days, then reintroduced at a lower daily dose. Some patients may be sensitive to treatment with Sulfasalazine. Various desensitization-like regimens have been reported to be effective in 34 of 53 patients,4 7 of 8 patients,5 and 19 of 20 patients.6 These regimens suggest starting with a total daily dose of 50 to 250 mg Sulfasalazine initially, and doubling it every 4 to 7 days until the desired therapeutic level is achieved. If the symptoms of sensitivity recur, Sulfasalazine should be discontinued. Desensitization should not be attempted in patients who have a history of agranulocytosis, or who have experienced an anaphylactoid reaction while previously receiving Sulfasalazine.

How is Sulfasalazine Supplied

Sulfasalazine Tablets USP are supplied as follows:

500 mg: Mustard-colored, round, biconvex, imprinted WATSON and 796 on one side and partial bisect on the other side, in bottles of 100, 500 and 1000.

Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]

REFERENCES

1. Mogadam M, et al. Pregnancy in inflammatory bowel disease: effect of Sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6.

2. Kaufman DW, editor. Birth defects and drugs during pregnancy. Littleton, MA: Publishing Sciences Group, Inc, 1977;296-313.

3. Jarnerot G. Fertility, sterility and pregnancy in chronic inflammatory bowel disease. Scand J Gastroenterol 1982;17:1-4.

4. Korelitz B, et al. Desensitization to Sulfasalazine in allergic patients with IBD: an important therapeutic modality. Gastroenterology 1982;82:1104.

5. Holdworth CG. Sulfasalazine desensitization. Br Med J 1981;282:110.

6. Taffet SL, Das KM. Desensitization of patients with inflammatory bowel disease to Sulfasalazine. Am J Med 1982;73:520-4.

Manufactured for:

Watson Laboratories, Inc.

Corona, CA 92880 USA

Manufactured by:

Patheon Pharmaceuticals Inc.

Cincinnati, OH 45215 USA

Rev: December 2003

70010592


Sulfasalazine (Sulfasalazine)
PRODUCT INFO
Product Code 0591-0796 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Sulfasalazine (Sulfasalazine) Active 500 MILLIGRAM  In 1 TABLET
Magnesium stearate Inactive  
Pregelatinized starch Inactive  
Sodium Starch glycolate Inactive  
Stearic acid Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color YELLOW (mustard) Score 2
Shape ROUND (Round) Symbol false
Imprint Code WATSON;796 Coating false
Size 12mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0591-0796-01 100 TABLET In 1 BOTTLE None
2 0591-0796-05 500 TABLET In 1 BOTTLE None
3 0591-0796-10 1000 TABLET In 1 BOTTLE None

Revised: 01/2007





Where can I get more information about Sulfasalazine Sulfasalazine Delayed Release Tablets ? We recommend to use www.Drugs.com

Typical mistypes for Sulfasalazine Sulfasalazine Delayed Release Tablets
aulfasalazine sulfasalazine delayed release tablets, zulfasalazine sulfasalazine delayed release tablets, xulfasalazine sulfasalazine delayed release tablets, dulfasalazine sulfasalazine delayed release tablets, eulfasalazine sulfasalazine delayed release tablets, wulfasalazine sulfasalazine delayed release tablets, sylfasalazine sulfasalazine delayed release tablets, shlfasalazine sulfasalazine delayed release tablets, sjlfasalazine sulfasalazine delayed release tablets, silfasalazine sulfasalazine delayed release tablets, s8lfasalazine sulfasalazine delayed release tablets, s7lfasalazine sulfasalazine delayed release tablets, sukfasalazine sulfasalazine delayed release tablets, supfasalazine sulfasalazine delayed release tablets, suofasalazine sulfasalazine delayed release tablets, suldasalazine sulfasalazine delayed release tablets, sulcasalazine sulfasalazine delayed release tablets, sulvasalazine sulfasalazine delayed release tablets, sulgasalazine sulfasalazine delayed release tablets, sultasalazine sulfasalazine delayed release tablets, sulrasalazine sulfasalazine delayed release tablets, sulfzsalazine sulfasalazine delayed release tablets, sulfssalazine sulfasalazine delayed release tablets, sulfwsalazine sulfasalazine delayed release tablets, sulfqsalazine sulfasalazine delayed release tablets, sulfaaalazine sulfasalazine delayed release tablets, sulfazalazine sulfasalazine delayed release tablets, sulfaxalazine sulfasalazine delayed release tablets, sulfadalazine sulfasalazine delayed release tablets, sulfaealazine sulfasalazine delayed release tablets, sulfawalazine sulfasalazine delayed release tablets, sulfaszlazine sulfasalazine delayed release tablets, sulfasslazine sulfasalazine delayed release tablets, sulfaswlazine sulfasalazine delayed release tablets, sulfasqlazine sulfasalazine delayed release tablets, sulfasakazine sulfasalazine delayed release tablets, sulfasapazine sulfasalazine delayed release tablets, sulfasaoazine sulfasalazine delayed release tablets, sulfasalzzine sulfasalazine delayed release tablets, sulfasalszine sulfasalazine delayed release tablets, sulfasalwzine sulfasalazine delayed release tablets, sulfasalqzine sulfasalazine delayed release tablets, sulfasalaxine sulfasalazine delayed release tablets, sulfasalasine sulfasalazine delayed release tablets, sulfasalaaine sulfasalazine delayed release tablets, sulfasalazune sulfasalazine delayed release tablets, sulfasalazjne sulfasalazine delayed release tablets, sulfasalazkne sulfasalazine delayed release tablets, sulfasalazone sulfasalazine delayed release tablets, sulfasalaz9ne sulfasalazine delayed release tablets, sulfasalaz8ne sulfasalazine delayed release tablets, sulfasalazibe sulfasalazine delayed release tablets, sulfasalazime sulfasalazine delayed release tablets, sulfasalazije sulfasalazine delayed release tablets, sulfasalazihe sulfasalazine delayed release tablets, sulfasalazinw sulfasalazine delayed release tablets, sulfasalazins sulfasalazine delayed release tablets, sulfasalazind sulfasalazine delayed release tablets, sulfasalazinr sulfasalazine delayed release tablets, sulfasalazin4 sulfasalazine delayed release tablets, sulfasalazin3 sulfasalazine delayed release tablets, sulfasalazine aulfasalazine delayed release tablets, sulfasalazine zulfasalazine delayed release tablets, sulfasalazine xulfasalazine delayed release tablets, sulfasalazine dulfasalazine delayed release tablets, sulfasalazine eulfasalazine delayed release tablets, sulfasalazine wulfasalazine delayed release tablets, sulfasalazine sylfasalazine delayed release tablets, sulfasalazine shlfasalazine delayed release tablets, sulfasalazine sjlfasalazine delayed release tablets, sulfasalazine silfasalazine delayed release tablets, sulfasalazine s8lfasalazine delayed release tablets, sulfasalazine s7lfasalazine delayed release tablets, sulfasalazine sukfasalazine delayed release tablets, sulfasalazine supfasalazine delayed release tablets, sulfasalazine suofasalazine delayed release tablets, sulfasalazine suldasalazine delayed release tablets, sulfasalazine sulcasalazine delayed release tablets, sulfasalazine sulvasalazine delayed release tablets, sulfasalazine sulgasalazine delayed release tablets, sulfasalazine sultasalazine delayed release tablets, sulfasalazine sulrasalazine delayed release tablets, sulfasalazine sulfzsalazine delayed release tablets, sulfasalazine sulfssalazine delayed release tablets, sulfasalazine sulfwsalazine delayed release tablets, sulfasalazine sulfqsalazine delayed release tablets, sulfasalazine sulfaaalazine delayed release tablets, sulfasalazine sulfazalazine delayed release tablets, sulfasalazine sulfaxalazine delayed release tablets, sulfasalazine sulfadalazine delayed release tablets, sulfasalazine sulfaealazine delayed release tablets, sulfasalazine sulfawalazine delayed release tablets, sulfasalazine sulfaszlazine delayed release tablets, sulfasalazine sulfasslazine delayed release tablets, sulfasalazine sulfaswlazine delayed release tablets, sulfasalazine sulfasqlazine delayed release tablets, sulfasalazine sulfasakazine delayed release tablets, sulfasalazine sulfasapazine delayed release tablets, sulfasalazine sulfasaoazine delayed release tablets, sulfasalazine sulfasalzzine delayed release tablets, sulfasalazine sulfasalszine delayed release tablets, sulfasalazine sulfasalwzine delayed release tablets, sulfasalazine sulfasalqzine delayed release tablets, sulfasalazine sulfasalaxine delayed release tablets, sulfasalazine sulfasalasine delayed release tablets, sulfasalazine sulfasalaaine delayed release tablets, sulfasalazine sulfasalazune delayed release tablets, sulfasalazine sulfasalazjne delayed release tablets, sulfasalazine sulfasalazkne delayed release tablets, sulfasalazine sulfasalazone delayed release tablets, sulfasalazine sulfasalaz9ne delayed release tablets, sulfasalazine sulfasalaz8ne delayed release tablets, sulfasalazine sulfasalazibe delayed release tablets, sulfasalazine sulfasalazime delayed release tablets, sulfasalazine sulfasalazije delayed release tablets, sulfasalazine sulfasalazihe delayed release tablets, sulfasalazine sulfasalazinw delayed release tablets, sulfasalazine sulfasalazins delayed release tablets, sulfasalazine sulfasalazind delayed release tablets, sulfasalazine sulfasalazinr delayed release tablets, sulfasalazine sulfasalazin4 delayed release tablets, sulfasalazine sulfasalazin3 delayed release tablets, sulfasalazine sulfasalazine selayed release tablets, sulfasalazine sulfasalazine xelayed release tablets, sulfasalazine sulfasalazine celayed release tablets, sulfasalazine sulfasalazine felayed release tablets, sulfasalazine sulfasalazine relayed release tablets, sulfasalazine sulfasalazine eelayed release tablets, sulfasalazine sulfasalazine dwlayed release tablets, sulfasalazine sulfasalazine dslayed release tablets, sulfasalazine sulfasalazine ddlayed release tablets, sulfasalazine sulfasalazine drlayed release tablets, sulfasalazine sulfasalazine d4layed release tablets, sulfasalazine sulfasalazine d3layed release tablets, sulfasalazine sulfasalazine dekayed release tablets, sulfasalazine sulfasalazine depayed release tablets, sulfasalazine sulfasalazine deoayed release tablets, sulfasalazine sulfasalazine delzyed release tablets, sulfasalazine sulfasalazine delsyed release tablets, sulfasalazine sulfasalazine delwyed release tablets, sulfasalazine sulfasalazine delqyed release tablets, sulfasalazine sulfasalazine delated release tablets, sulfasalazine sulfasalazine delaged release tablets, sulfasalazine sulfasalazine delahed release tablets, sulfasalazine sulfasalazine delaued release tablets, sulfasalazine sulfasalazine dela7ed release tablets, sulfasalazine sulfasalazine dela6ed release tablets, sulfasalazine sulfasalazine delaywd release tablets, sulfasalazine sulfasalazine delaysd release tablets, sulfasalazine sulfasalazine delaydd release tablets, sulfasalazine sulfasalazine delayrd release tablets, sulfasalazine sulfasalazine delay4d release tablets, sulfasalazine sulfasalazine delay3d release tablets, sulfasalazine sulfasalazine delayes release tablets, sulfasalazine sulfasalazine delayex release tablets, sulfasalazine sulfasalazine delayec release tablets, sulfasalazine sulfasalazine delayef release tablets, sulfasalazine sulfasalazine delayer release tablets, sulfasalazine sulfasalazine delayee release tablets, sulfasalazine sulfasalazine delayed eelease tablets, sulfasalazine sulfasalazine delayed delease tablets, sulfasalazine sulfasalazine delayed felease tablets, sulfasalazine sulfasalazine delayed telease tablets, sulfasalazine sulfasalazine delayed 5elease tablets, sulfasalazine sulfasalazine delayed 4elease tablets, sulfasalazine sulfasalazine delayed rwlease tablets, sulfasalazine sulfasalazine delayed rslease tablets, sulfasalazine sulfasalazine delayed rdlease tablets, sulfasalazine sulfasalazine delayed rrlease tablets, sulfasalazine sulfasalazine delayed r4lease tablets, sulfasalazine sulfasalazine delayed r3lease tablets, sulfasalazine sulfasalazine delayed rekease tablets, sulfasalazine sulfasalazine delayed repease tablets, sulfasalazine sulfasalazine delayed reoease tablets, sulfasalazine sulfasalazine delayed relwase tablets, sulfasalazine sulfasalazine delayed relsase tablets, sulfasalazine sulfasalazine delayed reldase tablets, sulfasalazine sulfasalazine delayed relrase tablets, sulfasalazine sulfasalazine delayed rel4ase tablets, sulfasalazine sulfasalazine delayed rel3ase tablets, sulfasalazine sulfasalazine delayed relezse tablets, sulfasalazine sulfasalazine delayed relesse tablets, sulfasalazine sulfasalazine delayed relewse tablets, sulfasalazine sulfasalazine delayed releqse tablets, sulfasalazine sulfasalazine delayed releaae tablets, sulfasalazine sulfasalazine delayed releaze tablets, sulfasalazine sulfasalazine delayed releaxe tablets, sulfasalazine sulfasalazine delayed releade tablets, sulfasalazine sulfasalazine delayed releaee tablets, sulfasalazine sulfasalazine delayed releawe tablets, sulfasalazine sulfasalazine delayed releasw tablets, sulfasalazine sulfasalazine delayed releass tablets, sulfasalazine sulfasalazine delayed releasd tablets, sulfasalazine sulfasalazine delayed releasr tablets, sulfasalazine sulfasalazine delayed releas4 tablets, sulfasalazine sulfasalazine delayed releas3 tablets, sulfasalazine sulfasalazine delayed release rablets, sulfasalazine sulfasalazine delayed release fablets, sulfasalazine sulfasalazine delayed release gablets, sulfasalazine sulfasalazine delayed release yablets, sulfasalazine sulfasalazine delayed release 6ablets, sulfasalazine sulfasalazine delayed release 5ablets, sulfasalazine sulfasalazine delayed release tzblets, sulfasalazine sulfasalazine delayed release tsblets, sulfasalazine sulfasalazine delayed release twblets, sulfasalazine sulfasalazine delayed release tqblets, sulfasalazine sulfasalazine delayed release tavlets, sulfasalazine sulfasalazine delayed release tanlets, sulfasalazine sulfasalazine delayed release tahlets, sulfasalazine sulfasalazine delayed release taglets, sulfasalazine sulfasalazine delayed release tabkets, sulfasalazine sulfasalazine delayed release tabpets, sulfasalazine sulfasalazine delayed release taboets, sulfasalazine sulfasalazine delayed release tablwts, sulfasalazine sulfasalazine delayed release tablsts, sulfasalazine sulfasalazine delayed release tabldts, sulfasalazine sulfasalazine delayed release tablrts, sulfasalazine sulfasalazine delayed release tabl4ts, sulfasalazine sulfasalazine delayed release tabl3ts, sulfasalazine sulfasalazine delayed release tablers, sulfasalazine sulfasalazine delayed release tablefs, sulfasalazine sulfasalazine delayed release tablegs, sulfasalazine sulfasalazine delayed release tableys, sulfasalazine sulfasalazine delayed release table6s, sulfasalazine sulfasalazine delayed release table5s, sulfasalazine sulfasalazine delayed release tableta, sulfasalazine sulfasalazine delayed release tabletz, sulfasalazine sulfasalazine delayed release tabletx, sulfasalazine sulfasalazine delayed release tabletd, sulfasalazine sulfasalazine delayed release tablete, sulfasalazine sulfasalazine delayed release tabletw, ulfasalazine sulfasalazine delayed release tablets, slfasalazine sulfasalazine delayed release tablets, sufasalazine sulfasalazine delayed release tablets, sulasalazine sulfasalazine delayed release tablets, sulfsalazine sulfasalazine delayed release tablets, sulfaalazine sulfasalazine delayed release tablets, sulfaslazine sulfasalazine delayed release tablets, sulfasaazine sulfasalazine delayed release tablets, sulfasalzine sulfasalazine delayed release tablets, sulfasalaine sulfasalazine delayed release tablets, sulfasalazne sulfasalazine delayed release tablets, sulfasalazie sulfasalazine delayed release tablets, sulfasalazin sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine ulfasalazine delayed release tablets, sulfasalazine slfasalazine delayed release tablets, sulfasalazine sufasalazine delayed release tablets, sulfasalazine sulasalazine delayed release tablets, sulfasalazine sulfsalazine delayed release tablets, sulfasalazine sulfaalazine delayed release tablets, sulfasalazine sulfaslazine delayed release tablets, sulfasalazine sulfasaazine delayed release tablets, sulfasalazine sulfasalzine delayed release tablets, sulfasalazine sulfasalaine delayed release tablets, sulfasalazine sulfasalazne delayed release tablets, sulfasalazine sulfasalazie delayed release tablets, sulfasalazine sulfasalazin delayed release tablets, sulfasalazine sulfasalazinedelayed release tablets, sulfasalazine sulfasalazine elayed release tablets, sulfasalazine sulfasalazine dlayed release tablets, sulfasalazine sulfasalazine deayed release tablets, sulfasalazine sulfasalazine delyed release tablets, sulfasalazine sulfasalazine delaed release tablets, sulfasalazine sulfasalazine delayd release tablets, sulfasalazine sulfasalazine delaye release tablets, sulfasalazine sulfasalazine delayedrelease tablets, sulfasalazine sulfasalazine delayed elease tablets, sulfasalazine sulfasalazine delayed rlease tablets, sulfasalazine sulfasalazine delayed reease tablets, sulfasalazine sulfasalazine delayed relase tablets, sulfasalazine sulfasalazine delayed relese tablets, sulfasalazine sulfasalazine delayed releae tablets, sulfasalazine sulfasalazine delayed releas tablets, sulfasalazine sulfasalazine delayed releasetablets, sulfasalazine sulfasalazine delayed release ablets, sulfasalazine sulfasalazine delayed release tblets, sulfasalazine sulfasalazine delayed release talets, sulfasalazine sulfasalazine delayed release tabets, sulfasalazine sulfasalazine delayed release tablts, sulfasalazine sulfasalazine delayed release tables, sulfasalazine sulfasalazine delayed release tablet, uslfasalazine sulfasalazine delayed release tablets, slufasalazine sulfasalazine delayed release tablets, suflasalazine sulfasalazine delayed release tablets, sulafsalazine sulfasalazine delayed release tablets, sulfsaalazine sulfasalazine delayed release tablets, sulfaaslazine sulfasalazine delayed release tablets, sulfaslaazine sulfasalazine delayed release tablets, sulfasaalzine sulfasalazine delayed release tablets, sulfasalzaine sulfasalazine delayed release tablets, sulfasalaizne sulfasalazine delayed release tablets, sulfasalaznie sulfasalazine delayed release tablets, sulfasalazien sulfasalazine delayed release tablets, sulfasalazin e sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine s ulfasalazine delayed release tablets, sulfasalazine uslfasalazine delayed release tablets, sulfasalazine slufasalazine delayed release tablets, sulfasalazine suflasalazine delayed release tablets, sulfasalazine sulafsalazine delayed release tablets, sulfasalazine sulfsaalazine delayed release tablets, sulfasalazine sulfaaslazine delayed release tablets, sulfasalazine sulfaslaazine delayed release tablets, sulfasalazine sulfasaalzine delayed release tablets, sulfasalazine sulfasalzaine delayed release tablets, sulfasalazine sulfasalaizne delayed release tablets, sulfasalazine sulfasalaznie delayed release tablets, sulfasalazine sulfasalazien delayed release tablets, sulfasalazine sulfasalazin edelayed release tablets, sulfasalazine sulfasalazined elayed release tablets, sulfasalazine sulfasalazine edlayed release tablets, sulfasalazine sulfasalazine dleayed release tablets, sulfasalazine sulfasalazine dealyed release tablets, sulfasalazine sulfasalazine delyaed release tablets, sulfasalazine sulfasalazine delaeyd release tablets, sulfasalazine sulfasalazine delayde release tablets, sulfasalazine sulfasalazine delaye drelease tablets, sulfasalazine sulfasalazine delayedr elease tablets, sulfasalazine sulfasalazine delayed erlease tablets, sulfasalazine sulfasalazine delayed rleease tablets, sulfasalazine sulfasalazine delayed reelase tablets, sulfasalazine sulfasalazine delayed relaese tablets, sulfasalazine sulfasalazine delayed relesae tablets, sulfasalazine sulfasalazine delayed releaes tablets, sulfasalazine sulfasalazine delayed releas etablets, sulfasalazine sulfasalazine delayed releaset ablets, sulfasalazine sulfasalazine delayed release atblets, sulfasalazine sulfasalazine delayed release tbalets, sulfasalazine sulfasalazine delayed release talbets, sulfasalazine sulfasalazine delayed release tabelts, sulfasalazine sulfasalazine delayed release tabltes, sulfasalazine sulfasalazine delayed release tablest, ssulfasalazine sulfasalazine delayed release tablets, suulfasalazine sulfasalazine delayed release tablets, sullfasalazine sulfasalazine delayed release tablets, sulffasalazine sulfasalazine delayed release tablets, sulfaasalazine sulfasalazine delayed release tablets, sulfassalazine sulfasalazine delayed release tablets, sulfasaalazine sulfasalazine delayed release tablets, sulfasallazine sulfasalazine delayed release tablets, sulfasalaazine sulfasalazine delayed release tablets, sulfasalazzine sulfasalazine delayed release tablets, sulfasalaziine sulfasalazine delayed release tablets, sulfasalazinne sulfasalazine delayed release tablets, sulfasalazinee sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine ssulfasalazine delayed release tablets, sulfasalazine suulfasalazine delayed release tablets, sulfasalazine sullfasalazine delayed release tablets, sulfasalazine sulffasalazine delayed release tablets, sulfasalazine sulfaasalazine delayed release tablets, sulfasalazine sulfassalazine delayed release tablets, sulfasalazine sulfasaalazine delayed release tablets, sulfasalazine sulfasallazine delayed release tablets, sulfasalazine sulfasalaazine delayed release tablets, sulfasalazine sulfasalazzine delayed release tablets, sulfasalazine sulfasalaziine delayed release tablets, sulfasalazine sulfasalazinne delayed release tablets, sulfasalazine sulfasalazinee delayed release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine sulfasalazine ddelayed release tablets, sulfasalazine sulfasalazine deelayed release tablets, sulfasalazine sulfasalazine dellayed release tablets, sulfasalazine sulfasalazine delaayed release tablets, sulfasalazine sulfasalazine delayyed release tablets, sulfasalazine sulfasalazine delayeed release tablets, sulfasalazine sulfasalazine delayedd release tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed rrelease tablets, sulfasalazine sulfasalazine delayed reelease tablets, sulfasalazine sulfasalazine delayed rellease tablets, sulfasalazine sulfasalazine delayed releease tablets, sulfasalazine sulfasalazine delayed releaase tablets, sulfasalazine sulfasalazine delayed releasse tablets, sulfasalazine sulfasalazine delayed releasee tablets, sulfasalazine sulfasalazine delayed release tablets, sulfasalazine sulfasalazine delayed release ttablets, sulfasalazine sulfasalazine delayed release taablets, sulfasalazine sulfasalazine delayed release tabblets, sulfasalazine sulfasalazine delayed release tabllets, sulfasalazine sulfasalazine delayed release tableets, sulfasalazine sulfasalazine delayed release tabletts, sulfasalazine sulfasalazine delayed release tabletss, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved